Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Saved in:
Bibliographic Details
Main Authors: Lee, Han-Chung, Hamzah, Hamizun, Leong, Melody Pui-Yee, Yusof, Hadri Md, Habib, Omar, Abidin, Shahidee Zainal, Seth, Eryse Amira, Lim, Siong-Meng, Vidyadaran, Sharmili, Moklas, Mohamad Aris Mohd, Abdullah, Maizaton Atmadini, Nordin, Norshariza, Hassan, Zurina, Cheah, Pike-See, Ling, King-Hwa
Format: Article
Published: Nature Research 2021
Subjects:
QL Zoology
R Medicine
R Medicine (General)
Online Access:http://eprints.um.edu.my/34626/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya

Internet

http://eprints.um.edu.my/34626/

Similar Items